BiotechTube
Abera Bioscience

Abera Bioscience

Stockholm, Sweden· Est.
aberabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.7M

Overview

Abera Bioscience is a clinical-stage biotech advancing a modular OMV platform for nasal vaccine delivery. Its lead program is a serotype-independent pneumococcal vaccine preparing for Phase 1, with a preclinical influenza candidate and platform potential for other infectious diseases. The company's strategy is to develop candidates to late preclinical/early clinical phases before seeking licensing partners, supported by non-dilutive funding from EU grants and organizations like CEPI. Leadership includes CEO Maria Alriksson and CSO Mats Lundgren, with foundational science from Prof. Joen Luirink.

Infectious Disease

Technology Platform

Modular Outer Membrane Vesicle (OMV) platform for nasal vaccine delivery. Enables display of antigenic proteins on bacterial-derived vesicles to induce strong mucosal and systemic immunity. Designed for rapid, cost-effective, scalable production and needle-free administration.

Funding History

2
Total raised:$3.7M
Seed$3.2M
Grant$500K

Opportunities

The platform's needle-free, potentially thermostable nasal spray format addresses critical needs in global health and pandemic preparedness, opening partnerships with entities like CEPI and Gavi.
A successful serotype-independent pneumococcal vaccine could disrupt a multi-billion dollar market dominated by injectable, serotype-specific products.

Risk Factors

High clinical development risk as the novel mucosal approach transitions from preclinical models to human trials.
Financial risk as a pre-revenue company dependent on raising capital in volatile markets.
Competitive risk from large pharma and other biotechs developing advanced vaccine platforms.

Competitive Landscape

Competes in the next-generation vaccine space against other companies developing mucosal vaccines (e.g., via viral vectors, live-attenuated, or other particle platforms) and OMV-based technologies. Faces significant competition from large, established vaccine manufacturers (GSK, Pfizer, Sanofi) who are also investing in novel platforms and intranasal delivery.

More companies in Biologics / Biosimilars →More companies in Sweden →